# Natasha Rekhtman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/natasha-rekhtman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,590 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 85 |
| i10-index | 188 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5078938585 |
| ORCID iD | 0000-0001-5801-3144 |
| Works | 608 |

## Researcher papers

Showing 12 of 22.

- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015](https://scholariq.org/papers/the-2021-who-classification-of-lung-tumors-impact-of-advances-since-2015/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy](https://scholariq.org/papers/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system](https://scholariq.org/papers/in-vivo-engineering-of-oncogenic-chromosomal-rearrangements-with-the-crispr-cas9/)
- [Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies](https://scholariq.org/papers/prospective-comprehensive-molecular-characterization-of-lung-adenocarcinomas-for/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping](https://scholariq.org/papers/response-to-met-inhibitors-in-patients-with-stage-iv-lung-adenocarcinomas/)
- [A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/a-grading-system-for-invasive-pulmonary-adenocarcinoma-a-proposal-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.